Skip to content
drillr.ai
Sign up

PRAX

Praxis Precision Medicines, Inc.

NASDAQ · Healthcare · Biotechnology · US

$351.81
−0.94%
Ask drillr

  • Aug 18, 2026, 07:45 UTC

    Praxis Precision Medicines, Inc. shares hit a new 52-week high of $391.64 during mid-day trading on Tuesday, last trading at $376.38 with volume of 581,487 shares.

    Source:

  • Aug 7, 2026, 08:04 UTC

    Praxis Precision Medicines is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and epileptic encephalopathies, as both new drug applications remain under FDA review.

    Source:

  • Aug 6, 2026, 00:00 UTC

    Praxis Precision Medicines reported a net loss of $83.72 million for Q2 2026, with diluted EPS of -$2.87, and held $1.4 billion in cash and investments as of June 30, 2026.

    Source:

  • Jul 7, 2026, 12:00 UTC

    Praxis Precision Medicines and Remagine Labs announced a research collaboration and license agreement to develop an iontophoretic transdermal patch for ulixacaltamide for essential tremor.

    Source:

  • Jul 2, 2026, 00:00 UTC

    Praxis Precision Medicines, Inc. dismissed Ernst & Young LLP as its auditor and engaged KPMG LLP as its new auditor.

  • Jun 29, 2026, 20:30 UTC

    The FDA extended the review period for Praxis Precision Medicines' New Drug Application for relutrigine, setting a new PDUFA date of December 27, 2026.

    Source:

  • Jun 22, 2026, 12:00 UTC

    Praxis Precision Medicines received FDA Breakthrough Therapy Designation for elsunersen for treating seizures associated with SCN2A-DEE caused by GoF variants.

    Source:

  • Jun 1, 2026, 20:15 UTC

    Praxis Precision Medicines reported Phase 2/3 POWER1 study results for vormatrigine in focal onset seizures, which did not meet its primary success measure but showed a secondary 50% response rate and good tolerability, and is pausing enrollment in the POWER2 study to reassess the program.

    Source: